Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) is on recovery track with 405.45% gain from a 1-year low price of $2.75. The company added 0.8% to attain the price of $13.9 on 6/19/2019. Throughout the recent session, the prices were hovering between $13.6 and $14.9. These shares are 56.47% off its target price of $21.75 and the current market capitalization stands at $306.49M. The recent change has given its price a 18.48% lead over SMA 50 and -15.6% deficit over its 52-week high. The stock witnessed -4.2% declines, 123.47% gains and 239.02% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ZYNE’s volatility during a week at 7.56% and during a month it has been found around 9.7%.
What Does Zynerba Pharmaceuticals, Inc. (ZYNE) Do?
The company describes itself in regulatory filings as, “Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments for rare and near-rare neurological and psychiatric, or neuropsychiatric, disorders in patients with high unmet medical needs. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.” [Text can be found here: https://www.marketwatch.com/investing/stock/ZYNE/profile under company description.]Zynerba Pharmaceuticals, Inc. (ZYNE) Top Holders
Institutional investors currently hold around $32 million or 12.8% in ZYNE stock. Look at its top three institutional owners: Vanguard Group Inc owns $7.46 million in Zynerba Pharmaceuticals, Inc., which represents roughly 2.43% of the company’s market cap and approximately 23.32% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 297,246 shares of the stock are valued at $4.1 million. The third largest holder is Campbell Capital Management Inc, which currently holds $2.49 million worth of this stock and that ownership represents nearly 0.81% of its market capitalization.
At the end of March reporting period, 30 institutional holders increased their position in Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) by some 718,349 shares, 31 decreased positions by 1,123,285 and 14 held positions by 466,684. That puts total institutional holdings at 2,308,318 shares, according to SEC filings. The stock grabbed 12 new institutional investments totaling 130,571 shares while 14 institutional investors sold out their entire positions totaling 853,047 shares.Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Insider Trades
Multiple company employees have indulged in significant insider trading. Zynerba Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Butler John P. has acquired 5,000 shares of Zynerba Pharmaceuticals, Inc. (ZYNE) in the trading session dated Aug. 22, 2018. These shares are worth $32,150 and were traded at $6.43 each. The SEC filing shows that Fickenscher James E performed a purchase of 8,518 shares. The CFO added these shares by way of transaction on Aug. 06, 2018. The company’s shares were assimilated at $5.97 per share worth to an investment of some $50,852 to the account of Fickenscher James E.
President, Sebree Terri B, purchased 3,800 common shares of Zynerba Pharmaceuticals, Inc. (ZYNE) in the open market. In a transaction dated Aug. 06, 2018, the shares were bought at an average price of $5.79, giving away a sum of $22,002. After this purchase, 182,546 common shares of ZYNE are directly owned by the insider, with total stake valued at $2,537,389.
In the transaction dated Aug. 06, 2018, a great number of shares acquired came courtesy the Sec, VP & General Counsel; Hanlon Suzanne M. added a total of 3,800 shares at an average price of $5.8, amounting to approximately $22,040. The insider now directly owns 43,693 shares worth $607,333.Zynerba Pharmaceuticals, Inc. (ZYNE) Analyst Guide
Several analysts have released their opinion on Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), with 2 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 3 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.83 average brokerage recommendation [T1].